Literature DB >> 2515025

Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.

G H Cassell1, K B Waites, M S Pate, K C Canupp, L B Duffy.   

Abstract

Lomefloxacin was found to be comparable to ciprofloxacin in its ability to inhibit the in vitro growth of Mycoplasma pneumoniae (MIC range 2-8 mcg/ml), but it was significantly less active than erythromycin. Although 30 different strains from widely differing geographic areas and isolation time periods were examined, no macrolide-resistant strains were observed.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2515025     DOI： 10.1016/0732-8893(89)90115-6

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  10 in total

1.  In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.

Authors:  K Hamamoto; T Shimizu; N Fujimoto; Y Zhang; S Arai
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

4.  In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors:  K B Waites; L B Duffy; T Schmid; D Crabb; M S Pate; G H Cassell
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

5.  In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.

Authors:  Y Gohara; S Arai; A Akashi; K Kuwano; C C Tseng; S Matsubara; M Matumoto; T Furudera
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 6.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

7.  Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.

Authors:  S Arai; Y Gohara; A Akashi; K Kuwano; M Nishimoto; T Yano; K Oizumi; K Takeda; T Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

8.  Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.

Authors:  T S Lucier; K Heitzman; S K Liu; P C Hu
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

9.  Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae.

Authors:  S Arai; Y Gohara; K Kuwano; T Kawashima
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

10.  Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.

Authors:  H Renaudin; C Bébéar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.